K Pharma,Inc.
Notice of Receipt of Domestic Patent Grant for Regenerative Medicine Business (Spinal Cord Injury)
Received a patent grant. Under an exclusive license with re-grantable sublicensing rights from Keio University, the IP foundation for the regenerative medicine pipeline centered on KP8011, including NeuroSphere manufacturing, selection, and therapeutic cell quality improvement, has been strengthened. Preparation for corporate clinical trials is progressing with a target start in 2027; overseas filings are ongoing. No impact on earnings forecasts for the fiscal year ending December 2026.
Key Figures
- Validity period and scope of granted patent: Unknown
- Planned start of clinical trials: During 2027
- Change to earnings forecast for fiscal year ending December 2026: None
AI要約
Key Points
Today we announce that a domestic patent related to our regenerative medicine business has been granted. We have received an exclusive license with re-grantable sublicensing rights from Keio University, the applicant, which strengthens the IP foundation contributing to the manufacture, selection, and quality improvement of therapeutic cells for NeuroSphere centered on KP8011. Overseas filings are also in progress. We are advancing preparations for corporate clinical trials with the aim of starting trials in 2027.
Outlook and Impact
By leveraging patents related to KP8011, we plan to accelerate corporate clinical trials and partnership activities. We expect to submit clinical trial notifications in 2027 and will pursue partnership negotiations with pharmaceutical companies to promote the early practical application of regenerative medicine products. This patent grant is expected to further strengthen the IP foundation of the regenerative medicine business and contribute to the long-term competitiveness of the business.
K Pharma,Inc.
Company overview · Stock price · Financial data · All IR
